firocoxib has been researched along with abt 116 in 1 studies
| Studies (firocoxib) | Trials (firocoxib) | Recent Studies (post-2010) (firocoxib) | Studies (abt 116) | Trials (abt 116) | Recent Studies (post-2010) (abt 116) |
|---|---|---|---|---|---|
| 102 | 43 | 71 | 5 | 3 | 4 |
| Protein | Taxonomy | firocoxib (IC50) | abt 116 (IC50) |
|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | 0.277 | |
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | 0.011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Nadaf, S; Budsberg, SC; Cathcart, CJ; Johnston, SA; Reynolds, LR | 1 |
1 trial(s) available for firocoxib and abt 116
| Article | Year |
|---|---|
Efficacy of ABT-116, an antagonist of transient receptor potential vanilloid type 1, in providing analgesia for dogs with chemically induced synovitis.
Topics: 4-Butyrolactone; Analgesia; Animals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Indazoles; Injections, Intra-Articular; Lameness, Animal; Male; Phenylurea Compounds; Stifle; Sulfones; Synovitis; TRPV Cation Channels; Uric Acid | 2012 |